Evaluation of the effect of oral curcumin on liver enzymes and liver T2*MRI

Evaluation of the effect of oral curcumin on liver enzymes and liver T2*MRI in patients with major and intermediate thalassemia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201107049296N1

Enrollment

Registered

2021-08-31

Start date

2021-09-01

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thalassemia. Thalassemia

Interventions

Intervention 1: Intervention group: receive 500 mg curcumin tablet (Razak pharmaceutical product) every 12 hours. Intervention 2: Control group: receive placebo pill every 12 hours.

Eligibility

Sex/Gender

All

Age

5 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with major and intermediate thalassemia

Exclusion criteria

Exclusion criteria: Parental dissatisfaction Renal failure Hepatitis B Hepatitis C AIDS

Design outcomes

Primary

Measure	Time frame
Alanine Aminotransferase. Timepoint: Measurement of serum Alanine Aminotransferase (ALT) levels At the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of curcumin administration. Method of measurement: Blood test.;Alkaline Phosphatase. Timepoint: Measurement of serum Alkaline Phosphatase (ALP) levels at the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of curcumin administration. Method of measurement: Blood test.;Aspartate Aminotransferase. Timepoint: Measurement of serum Aspartate Aminotransferase (AST) levels at the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of curcumin administration. Method of measurement: Blood test.;Total Bilirubin. Timepoint: Measurement of serum Total Bilirubin levels at the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of curcumin administration. Method of measurement: Blood test.;Direct Bilirubin. Timepoint: Measurement of serum Direct Bilirubin levels at the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of curcumin administration. Method of measurement: Blood test.;Ferritin. Timepoint: Measurement of serum ferritin levels at the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of curcumin administration. Method of measurement: Blood test.;Liver T2MRI. Timepoint: Measurement of liver T2MRI at the beginning of the study and 6 months after initiation of curcumin administration. Method of measurement: Magnetic Rsonance Imaging.	—

Measure

Time frame

Alanine Aminotransferase. Timepoint: Measurement of serum Alanine Aminotransferase (ALT) levels At the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of curcumin administration. Method of measurement: Blood test.;Alkaline Phosphatase. Timepoint: Measurement of serum Alkaline Phosphatase (ALP) levels at the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of curcumin administration. Method of measurement: Blood test.;Aspartate Aminotransferase. Timepoint: Measurement of serum Aspartate Aminotransferase (AST) levels at the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of curcumin administration. Method of measurement: Blood test.;Total Bilirubin. Timepoint: Measurement of serum Total Bilirubin levels at the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of curcumin administration. Method of measurement: Blood test.;Direct Bilirubin. Timepoint: Measurement of serum Direct Bilirubin levels at the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of curcumin administration. Method of measurement: Blood test.;Ferritin. Timepoint: Measurement of serum ferritin levels at the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of curcumin administration. Method of measurement: Blood test.;Liver T2*MRI. Timepoint: Measurement of liver T2*MRI at the beginning of the study and 6 months after initiation of curcumin administration. Method of measurement: Magnetic Rsonance Imaging.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contact?Aziz Eghbali

Iran University of Medical Sciences

eghbali.a@iums.ac.ir+98 21 2222 2041

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026